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Methods: In 1045 patients treated with peg-interferon and riba-
virin, two therapeutic strategies were confronted: the ﬁrst one
evaluated only baseline variables associated with sustained viro-
logical response (SVR), and the second one included the rapid
virologic response (RVR) in addition to baseline predictors. An
80% SVR rate was the threshold to retain a strategy as clinically
relevant.
Results: Overall, 414 patients (39.6%) attained SVR. In the ﬁrst
strategy, the hierarchy of features independently associated with
SVR was IL28B CC genotype (OR 5.082; CI 3.637–7.101), low
(<400,000 IU) viremia (OR 2.907; CI 2.111–4.004), F0–F2 ﬁbrosis
(OR 1.631; CI 1.122–2.372) and type 2 diabetes (OR 0.528; CI
0.286–0.972). In the alternative strategy, SVR was associated
with RVR (OR 6.273; CI 4.274–9.208), IL28B CC genotype (OR
3.306; CI 2.301–4.751), low viremia (OR 2.175; CI 1.542–3.070),
and F0–F2 ﬁbrosis (OR 1.506; CI 1.012–2.242). Combining theJournal of Hepatology 20
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E-mail address: a.andriulli@operapadrepio.it (A. Andriulli).favorable baseline variables, the rates of SVR ranged from 42.4%
to 83.3%, but only 66 patients (6.3%, overall) with all predictors
could be anticipated to reach the >80% SVR threshold. Only
26.6% of no-RVR patients attained SVR. Among the 255 RVR
patients, the likelihood of SVR was 61.8% in those with unfavor-
able predictors, 80% in the presence of a single predictor, and
100% when both predictors were present. By using this model,
200 patients (19.1%) were predicted to have an 80% chance of
being cured with dual therapy.
Conclusions: A consistent subset of naïve HCV-1 patients, identi-
ﬁed by some baseline characteristics and RVR, may beneﬁt from
dual treatment with peg-interferon and ribavirin.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
There have been signiﬁcant changes in the management of
patients with HCV genotype 1 (HCV-1) infection since the
approval of the two HCV NS3/4A serine protease inhibitors
(PIs), telaprevir and boceprevir, by regulatory agencies. The addi-
tion of PIs to the previous standard of care, Peg-interferon
(PegIFN) and ribavirin (RBV), has boosted the sustained virologic
response (SVR) to approximately 75% in treatment-naïve patients
[1,2]. Echoing these results, scientiﬁc communities [3,4] and gov-
ernmental health care organizations [5] recommended triple14 vol. 60 j 16–21
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therapies with PegIFN, RBV, and PIs as the new standard of care
for genotype 1 untreated and previously treated patients. The
therapeutic advances with triple therapies came at the expenses
of increased adverse effects, signiﬁcant drug-drug interactions,
and induction of viral mutations. In addition, despite positive
cost-effective analyses [6,7] and better outcomes than dual ther-
apy, the use of triple therapy is associated with increased costs,
which may threaten to maintain a disparity in access to care.
Especially for countries with signiﬁcant disease burden of HCV
infection and real budgetary and resource constraints, the
expense of these new regimens may make the interferon regi-
mens more reasonable.
Despite the gain in SVR rates provided by triple therapies, it
remains that conventional dual therapies may achieve SVR in
40–50% of naïve patients with HCV-1 infection [8]. The ability
to identify patients likely to achieve high SVR rates following dual
therapies appears clinically valuable and appropriate for short-
term budgeting. Several virus and patient features, such as serum
HCV RNA levels and the degree of ﬁbrosis, markedly affect the
likelihood of attaining an SVR, whereas other inﬂuential factors
with lesser impact include age, gender, race, and body weight/
body mass index [9,10]. Recent data have further highlighted that
the favorable IL28B polymorphism rs12979860 [11] and/or the
achievement of rapid virologic response (RVR) [12] may identify
patients who stand to beneﬁt the most from PegIFN and RBV. By
adopting baseline predictors of SVR as a criterion to allocate
treatment-naïve patients to dual or triple therapies, it could be
possible to initiate conventional regimens in those with favorable
predictors, and to offer ab initio triple therapy to those less likely
to beneﬁt from standard therapy and for whom the increased risk
of side-effects and the increased cost of drugs may be most justi-
ﬁed. The alternative strategy would be to test all candidates to
therapy for interferon sensitivity at week 4 from starting dual
therapy, and add on PIs only to those with poor responsiveness.
The magnitude of the pool of patients who need to be allocated
to dual or triple therapies remains to be exactly quantiﬁed.
Objective of this large, non-interventional cohort study on
genotype 1 chronic HCV infection was to provide a realistic esti-
mate of the proportion of patients who might beneﬁt from dual
antiviral therapy. To accomplish this, we considered two alterna-
tive strategies for allocating treatment: the ﬁrst one reserving
PegIFN and RBV to the subset of patients with favorable predic-
tors of SVR at baseline, and the second one restricting this regi-
men to those with interferon sensitivity, as ascertained by
negative HCV viremia at week 4 from the start of therapy. As
PIs-based triple therapy has boosted SVR rates to approximately
75% [1,2], a strategy that still contemplates the option of dual
therapy for HCV-1 previously untreated patients had to guaran-
tee for an SVR rate of >80% to be considered as clinically relevant.Materials and methods
Patients
Current retrospective analysis refers to HCV-1 patients treated with PegIFN and
RBV at 15 Italian centers from 2005 to 2010. The database at each participating
institution was interrogated for patients who were naïve to antiviral treatment,
and presented with an initial diagnosis of chronic hepatitis or compensated liver
cirrhosis. For this analysis, HBV and HIV co-infected patients were excluded.
Of the 2359 HCV-1 infected patients deposited into the databases, 1045 indi-
viduals (44,3%)were retained in theﬁnal analysis.Weexcludedbyprotocol patients
who withdrew treatment by week 24 due to intolerance or severe side effectsJournal of Hepatology 20(n = 195), those non consenting to IL28B genotyping (n = 365), those lost to fol-
low-up (n = 294), those who had died (n = 82), and those with missing viremia
results atweek4of therapy (n = 213), orwithmissinghistologic or FibroScan eval-
uation (n = 165) (Fig. 1). Patients received either PegIFNa-2b ora-2a plus ribavirin.
To comply with treatment guidelines, patients with negative HCV RNA at week 12
continued treatment for 48 weeks, whereas therapywas halted atweek 24 in those
with persistent viremia. Patients with low serum HCV RNA levels (lower than
400,000 IU/ml) at baseline who achieved an RVR had to stop therapy at week 24.
At the time of the recall visit, information about the latest HCV RNA testing, liver
chemistry, and abdominal ultrasound was recorded. The study was approved by
ethics committees, and conducted according toprovisionsof theDeclaration ofHel-
sinki and Good Clinical Practice Guidelines.
Genotyping of IL28B rs12979860 polymorphism
IL28B rs12979860 SNP was genotyped using the TaqMan SNP genotyping kit (ABI
ABI TaqMan) and the ABI 7900HT sequence detection System (Applied Biosys-
tems, Foster City, CA, USA).
Viral load and HCV genotyping
HCV genotyping was performed by the commercially available Inno-LiPA assay
(Innogenetics, Zwijndrecht, Belgium). Serum HCV RNA was quantiﬁed at baseline
by reverse transcription-PCR, using the Cobas Amplicor HCV Monitor Test, v 2.0
(Roche, Basel, Switzerland). Qualitative HCV RNA assessment was made at weeks
4, 24, and 48 during treatment, and at week 24 after stopping therapy. Rapid viro-
logic response (RVR) was deﬁned as undetectable HCV RNA in serum at week 4 of
therapy, and SVR as undetectable HCV RNA in serum 24 weeks after stopping
therapy.
Assessing the degree of hepatic ﬁbrosis
Histologic data were available for 660 patients who consented to liver biopsy, and
classiﬁed by local pathologists according to different scoring systems, which were
then converted to uniform criteria as the Metavir score [13]. In the remaining
patients, cirrhosis was diagnosed on the occurrence of one or more following cri-
teria: a liver elastometric (FibroScan) valueP13kPa, and/or oesophageal varices
at endoscopy, and/or platelet count <100,000/ml [14,15]. To ascertain the pres-
ence of F3 ﬁbrosis, the following criteria were followed: a FibroScan value <13
but P9 kPa, and/or platelet count >100,000 but <140,000/ml [16–17].
Statistical analysis
All data were analyzed on the intention to treat basis using SPSS 13.0 for Win-
dows software (SPSS Inc., Chicago, IL. USA). Differences between continuous vari-
ables, expressed as medians and Interquartile Ranges (IQR), were analyzed using
non-parametric Mann-Whitney Test, whereas Chi-square and Fisher’s exact test
were used for categorical variables. The association between baseline features
and SVR was calculated using multiple logistic regression analysis. The ﬁrst
model was stratiﬁed by a set of cohort characteristics at baseline, including age
(<vs. P50 years), gender, BMI, serum alanine aminotransferase (ALT) levels, liver
ﬁbrosis stage (F0–F2 vs. F3–F4), HCV genotype (1a vs. 1b), baseline viral load (<vs.
P400,000 IU/ml) [18], IL28B genotypes (CC vs. CT/TT), the occurrence of diabetes,
and the type of PegIFN (alpha-2a vs. alpha 2b). The second model incorporated
RVR along with baseline variables. Variables with a threshold value of p <0.10
at univariate analysis were included in the models, and only variables with a
threshold value of p <0.05 were retained in the ﬁnal model. The results were
expressed as odds ratios (OR) with corresponding 95% Conﬁdence Interval (CI).
Finally, patients were sub-grouped according to the previously identiﬁed predic-
tors in order to select the ones with a >80% likelihood of attaining SVR following
PegIFN and RBV.Results
Patient characteristics (Table 1)
A total of 1045 Caucasian patients were recruited for the
study. A majority of patients were males (57.4%), older than
50 years (63.2%), infected by HCV-1 subtype 1b (86%), and14 vol. 60 j 16–21 17
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with high (P400,000 IU/ml) viral load (68.4%). As to the IL28B
polymorphisms, 277 (26.5%) patients were homozygous for the
CC allele, 548 (52.4%) heterozygous for CT, and 220 (21.1%)
homozygous for TT. PegIFN alpha-2a was administered to
61.9% of the patients, and PegIFN alpha-2b to the remaining
individuals. RBV was given at a mean dosage of 14 ± 2 mg/kg
of body weight.
Efﬁcacy of treatment and factors associated with SVR (Table 1)
By intention-to-treat analysis, 414 patients (39.6%) attained an
SVR. Among the 255 patients (24.4%) who achieved RVR, 204
individuals cleared the virus following therapy (80%).
At univariate analysis, age (dichotomized at 50 years), blood
glucose values, platelet counts, serum HCV RNA levels (dichoto-
mized at 400,000 UI/ml), genotypes of the rs12979860 SNP (CC
vs. CT/TT) and staging of ﬁbrosis (F0/F2 vs. F3/F4) were signiﬁ-
cantly associated with SVR (p <0.05) (Table 1). We analyzed theTable 1. Univariate analysis of baseline feature and rapid virological response assoc
Variables Overall
n = 1045
Sex (No., %)  
Male 600 (57.4)
Female 445 (42.6)
Age (No., %)
<50 yr 383 (36.7)
≥50 yr 662 (63.2)
Body mass index (kg/m2)~ 25 (23-28)
ALT (ULN)~ 2 (1-3)
Platelet count (x103/mm³)~ 200 (151-235)
Stage F0-F2
Liver fibrosis (No., %)
664 (63.5)
Stage F3-F4 381 (36.5)
Type 2 diabetes (No., %) 
Yes 110 (10.5)
No 935 (89.5)
HCV genotypes* (No., %)
1a 144 (14.0)
1b 885 (86.0)
Serum HCV RNA levels (No., %)
<400.000 IU/ml 330 (31.6)
≥400.000 IU/ml 715 (68.4)
IL28B rs12979860 SNP (No., %)
CC 277 (26.5)
CT 548 (52.4)
TT 220 (21.1)
Type of PegIFN (No., %)
PegIFN-α2a 647 (61.9)
PegIFN-α2b 398 (38.1)
RVR 255 (24.4)
no RVR 790 (75.6)
⁄ Undifferentiated subtype (n = 16).
 (Median, IQR).
18 Journal of Hepatology 20treatment duration in patients with low HCV RNA levels at base-
line. Among 123 patients who achieved RVR and had baseline
serum HCV-RNA levels <400,000 IU/ml, 33 individuals were trea-
ted for 24 weeks and 27 of them (82%) achieved an SVR; of the
remaining 90 patients treated for 48 weeks, 81 subjects (90%)
eventually cleared the infection.
At multivariate analysis (Table 2), the hierarchy of baseline
factors independently associated with SVR (model A) were the
CC genotype of the IL28B locus (OR 5.082; CI 3.637–7.101), serum
HCV-RNA levels <400,000 IU/ml (OR 2.907; CI 2.111–4.004), F0–
F2 ﬁbrosis (OR 1.631; CI 1.122–2.372) and type 2 diabetes (OR
0.528; CI 0.286–0.972). When the RVR status was included
among predictors of SVR (model B), the hierarchy of factors inde-
pendently associated with SVR at multivariate analysis was RVR
(OR 6.273; CI 4.274–9.208), CC genotype of the IL28B locus (OR
3.306; CI 2.301–4.751) serum HCV-RNA levels <400,000 IU/ml
(OR 2.175; CI 1.542–3.070) and F0–F2 ﬁbrosis (OR 1.506; CI
1.012–2.242).iated with sustained virological response (SVR) in 1045 patients.
No SVR
n = 631 (60.4%) 
SVR
n = 414 (39.6%) 
Univariate
analysis
p value
374 ( 62.3) 226 (37.7) 0.134
257 (57.8) 188 (42.2)
200 (52.2) 183 (47.8) <0.001
431 (65.1) 231 (34.9)
26 (23-28) 25 (22-27) 0.012
2 (1.3-3) 1.98 (1.15-3) 0.263
199 (144-235) 205 (168-237) 0.002
365 (55.0) 299 (45.0) <0.001
266 (69.8) 115 (30.2)
80 (72.7) 30 (27.3) 0.005
551 (58.9) 384 (41.1)
79 (54.9) 65 (45.1) 0.154
541 (61.1) 344 (38.9)
151 (45.8) 179 (54.2) <0.001
480 (67.1) 235 (32.9)
93 (33.6) 184 (66.4) <0.001
384 (70.1) 164 (29.9)
154 (70.0) 66 (30.0)
394 (60.9) 253 (39.1) 0.665
237 (59.5) 161 (40.5)
51 (20.0) 204 (80.0) <0.001
580 (73.4) 210 (26.6)  
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Patients overall (n = 2359)
Excluded patients (n = 1314)
Evaluated  patients (n = 1045)
Lost to follow-up (n = 294)
Death (n = 82)
Refused IL28B testing (n = 365)
Unable to reach 24 weeks treatment duration (n = 195)
Missing RVR status (n =213)
Missing liver biopsy or fibroscan evaluation (n = 165)
Reasons:
Fig. 1. Flow of patients enrolled into the study.
Table 2. Multivariate analysis of baseline feature (Model A) and baseline feature and rapid virological response (Model B) associated with sustained virological
response (SVR) in 1045 patients.
Variables Multivariate analysis
Model A Model B
OR (95% CI) p value OR (95% CI) p value
Age <50 yr 1.35 (0.991-1.833) 0.06 1.33 (0.960-1.851) 0.086
Body mass index 0.98 (0.946-1.016) 0.27 0.98 (0.940-1.014) 0.214
Platelet count 1.00 (0.998-1.003) 0.65 1.00 (0.998-1.003) 0.819
1.63 (1.122-2.372) 0.01 1.51 (1.012-2.242) 0.043
Type 2 diabetes 
Liver fibrosis (F0-F2)
0.53 (0.286-0.972) 0.04 0.58 (0.306-1.115) 0.103
Serum HCV RNA levels (<400.000 IU/ml) 2.91 (2.111-4.004) <0.001 2.17 (1.542-3.070) <0.001
IL28B rs12979860 (CC) 5.08 (3.637-7.101) <0.001 3.31 (2.301-4.751) <0.001
RVR - - 6.27 (4.274-9.208) <0.001
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Fig. 2. Sustained virologic response rates following PegIFN/RBV in 1045 HCV
genotype 1 patients. (A) Stratiﬁed according to independent predictors for SVR at
baseline; (B) stratiﬁed according to baseline predictors and on-treatment
virologic response. IL28B CC or TT or CT = IL28B polymorphism rs12979860.
RVR, rapid virologic response.
JOURNAL OF HEPATOLOGYEstimating the pool of patients who could achieve SVR following dual
therapy
By using data from model A (Fig. 2A), 768 patients with CT or TT
genotype at the rs12979860 SNP had a 29.9% likelihood of achiev-
ing SVR. By combining independent baseline features associated
with SVR, the probability of achieving SVR ranged from 42.4%
to 83.3%. In patients carrying the CC genotype, the SVR rate
was 42.4% when the other two unfavourable predictors (i.e.,
F3–F4 ﬁbrosis and serum HCV-RNA levelsP400,000 IU/ml) were
concomitantly present, and increased to values of 74.1% and
68.6%, when a single favourable predictor was detected. Only in
the subset of patients displaying all three favourable factors (CC
genotype, F0–F2 ﬁbrosis, and serum HCV-RNA levels
<400,000 IU/ml) the SVR rate was clinically relevant (83.3%),
but this condition was present in only 55 out of the total 1045
HCV-1 patients, a marginal proportion of 5.3%.
When we incorporated the RVR status (model B) to baseline
predictors, the prediction power for SVR among different sub-
groups of patients increased substantially (Fig. 2B). Only 26.6%
of patients without RVR attained SVR, whereas among the 255
RVR patients, the likelihood of SVR was 68.0% in patients with
concomitant unfavorable predictors (no-CC genotype and high
viremia), but did attain the clinically signiﬁcant threshold of
80% when one positive predictor happened to be present. When-
ever RVR carriers of the CC genotype presented with low viremia,Journal of Hepatology 20100% of them cleared HCV following dual therapy. By using this
model, 200 of the entire cohort of 1045 patients (19.1%) could
be predicted at week 4 of therapy to have an 80% chance of being
cured with dual therapy.
Stratifying RVR patients by hepatic ﬁbrosis
Even if the prediction power of hepatic ﬁbrosis was inferior to the
other factors, we evaluated the inﬂuence of the stage of hepatic
ﬁbrosis on SVR in our 255 patients who cleared the HCV at14 vol. 60 j 16–21 19
Table 3. Sustained virological response (SVR) rates following peg-interferon
and ribavirin in 255 genotype 1 patients with rapid (week 4) virologic
response, stratiﬁed according to the stage of liver ﬁbrosis.
RVR n = 255
  Total SVR 
 n % n %
F0-F2
n = 186 CC + low viremia 42 22.6 42 100.0
CC + high viremia 55 29.6 47 85.5
no CC + low viremia 53 28.5 42 79.2
no CC + high viremia 36 19.3 20 55.6
F3-F4
n = 69 CC + low viremia 11 15.9 11 100.0
CC + high viremia 22 31.9 15 68.2
no CC + low viremia 17 24.6 13 76.5
 no CC + high viremia 19 27.6 14 73.7
Research Articletreatment week 4 (Table 3). In the 186 patients with absent/mod-
erate ﬁbrosis (F0–F2), SVR rates were optimal (>80%) in those
presenting with a single or two positive predictors of SVR, but
were suboptimal (55.6%) in those with IL28B CT/TT genotypes
and high viremia. Among the 69 RVR patients with advanced
ﬁbrosis/cirrhosis, SVR rates were high only in cases with low
viremia.Discussion
When considering therapy for patients chronically infected by
HCV genotype 1, ﬁnding the optimal balance between managing
therapy-related adverse effects and costs, as well as optimizing
the chance of SVR after conventional or new antiviral therapies
are major challenges. Because the new antiviral regimens still
involve PegIFN [1,2], the likelihood of success will continue to
rely on the interferon responsiveness. In this large cohort of
1045 patients, we have shown that on-treatment virologic
response, speciﬁcally the HCV RNA undetectability at week 4,
was dominant over all other variables at determining the likeli-
hood of SVR following PegIFN and ribavirin.
In our population, an RVR was achieved by 255 (24.4%)
patients, and 204 of them (80%) attained SVR. At multivariate
analysis (Table 2), the prediction ability of RVR for an SVR was
about 2-fold higher than that of the CC genotype of IL28B, and
about 3-fold stronger than that of low viremia. The low predictive
power of IL28B genotyping for SVR in our series of Caucasian
patients with chronic HCV infection deserves a comment. Of
the 277 patients homozygous for the CC allele, only 47% and
66% were capable of attaining RVR and SVR, respectively, after
conventional dual therapy. In addition, of 70 no-CC genotype
patients with RVR and low viremia, 55 individuals (78.6%,
Fig. 2B) experienced SVR. Similar to reports from Thompson
et al. [19] and Di Marco et al. [20], the weak utility of the IL28B
genotype for predicting an optimal treatment outcome, once
RVR was determined, could suggest that the major effect of the
IL28B polymorphism was to inﬂuence viral kinetics within the
initial months of therapy. As a matter of fact, among our patients
with RVR more than 80% eventually cleared the infection follow-
ing conventional dual therapy, the only exception being those
with no-CC genotype and high viremia (Fig. 2B).20 Journal of Hepatology 20In addition, our data provide potentially valuable information
on how to predict the likelihood of SVR, and which patients to
prioritize for treatment with triple therapies. As to the ﬁrst issue,
none of the pretreatment factors, namely the IL28B genotype, the
viral load, and the ﬁbrosis stage, accurately predicted response to
therapy for an individual patient. Indeed, individuals with poor
predictors may still respond to therapy, as it was the case for
29.9% of our 768 patients carrying the IL28B gene CT or TT types,
30.2% of 381 patients with advanced ﬁbrosis, and 32.9% of 715
patients with high viremia. Consequently, in the clinical assess-
ment of an individual patient, neither carriage of ‘‘poor-progno-
sis’’ IL28B rs12979860 genotypes nor high viral load or
signiﬁcant hepatic ﬁbrosis would preclude the chance of SVR. In
the present study, by relying on the three identiﬁed independent
predictors for SVR (i.e., IL28B CC type, low viremia, and F0–F2
ﬁbrosis), only 66 individuals (6.3% overall) could have been iden-
tiﬁed before starting therapy as having a high (>80%) chance of
SVR following conventional dual therapy. On the contrary, by
considering the RVR status, 200 patients (19.1%, overall) would
be deemed at high likelihood of SVR following PegIFN and RBV.
This observation suggests that it does not matter, which baseline
feature HCV-infected patients present with, but rather how they
achieve early undetectable HCV RNA. Actual on-treatment viral
responses provide the clinical trump card of response prediction
for PegIFN and RBV regimens: as long as patients continue treat-
ment with dual therapy after reaching this virological landmark,
they are at high likelihood of achieving an SVR.
The degree of hepatic ﬁbrosis is one of the currently followed
criteria to tailor treatment success and duration in the HCV geno-
type 1 [9,10]. However, in the present investigation, this charac-
teristic was picked up at multivariate analysis as having an
independent prediction power for SVR when only baseline fea-
tures were evaluated in Model A. However, the negative inﬂuence
of advanced ﬁbrosis on SVR rates was obscured in our cohort of
patients when the RVR status was included into the analysis
along with other baseline predictors (Model B) [21]. This would
indicate that patients with advanced ﬁbrosis or cirrhosis who
carry the CC IL28 genotype and present with low viremia are
likely to respond favorably to PegIFN and RBV in the event they
achieve an RVR. Finally, our data conﬁrm patients with mild or
moderate ﬁbrosis and low viral load have the same probability
of obtaining an SVR when treated for a short (24 weeks) or stan-
dard duration of therapy (48 weeks), as originally pointed out by
Zeuzem et al. [22].
The major implication of recommending triple rather than
dual therapy for the universal population of HCV 1 infected
patients is that more patients would achieve viral load reduction
at week 4, as shown by trials on combination therapy of a direct
antiviral agent with PegIFN and ribavirin. However, because Peg-
IFN and RBV can cause burdensome adverse effects and treat-
ment is prolonged, HCV protease inhibitors will add signiﬁcant
morbidity. In this study, we estimated that 24.4% of 1045 patients
with chronic HCV infection were capable to achieve RVR, a per-
centage in keeping with that reported in a recent systematic
review of literature data on this topic [12]. These ﬁndings lend
support to a risk-stratiﬁcation of patients according to interferon
responsiveness at treatment week 4 before the addition of prote-
ase inhibitors [1,2]. In order to optimize the risk/beneﬁt ratio of
combination therapies, we would recommend to initiate antiviral
treatment in all naïve patients with chronic HCV infection,
regardless of their presenting features, and to keep on with14 vol. 60 j 16–21
JOURNAL OF HEPATOLOGY
standard conventional therapy in those with RVR and other pre-
dictors of SVR.
In conclusion, the growing enthusiasm about embracing new
therapies should not obscure the notion that an appreciable num-
ber of HCV-1 infected patients are able to eliminate the virus with
conventional dual therapies. We estimated the magnitude of
these patients to amount to 20%, a ﬁgure which is constituted
by the great majority of patients experiencing RVR.Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.
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